Luis Martinez, MD
Internal Medicine · Doral, FLNPI 1972605533
Payments from drug & device makers
Across 711 payments — averaging $19,446 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5.3M
- Genentech, Inc.$2.8M
- Modernatx, Inc.$2.2M
- Abbott$860K
- GSK$736K
- AbbVie$544K
- plus $1.4M from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 106 | $5,323,202 |
| Genentech, Inc. | 58 | $2,783,009 |
| Modernatx, Inc. | 121 | $2,154,906 |
| Abbott | 51 | $860,404 |
| GSK | 36 | $735,955 |
| AbbVie | 83 | $543,505 |
| Astrazeneca UK Limited | 8 | $275,839 |
| Merck | 13 | $198,861 |
| Noven Pharmaceuticals, Inc. | 17 | $192,152 |
| Organon | 21 | $185,500 |
| Novartis | 6 | $138,670 |
| AstraZeneca(2 entities) | 4 | $121,792 |
| Bristol Myers Squibb | 12 | $70,156 |
| Janssen Research & Development, LLC | 10 | $54,051 |
| Boehringer Ingelheim | 8 | $43,074 |
| Livanova USA, Inc. | 12 | $34,267 |
| Gilead | 8 | $27,454 |
| Amgen | 31 | $25,927 |
| Averitas Pharma Inc. | 8 | $24,894 |
| Boehringer Ingelheim Canada Ltd.ltee | 28 | $22,350 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Boehringer Ingelheim International GmbH | 10 | $1,966 |
| Novo Nordisk | 20 | $414 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $187 |
| Sight Sciences, Inc. | 1 | $142 |
| Teva Pharmaceuticals USA, Inc. | 6 | $135 |
| Exact Sciences | 4 | $101 |
| Lilly USA, LLC | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 3 | $75 |
| Intuitive Surgical | 1 | $60 |
| Amarin Pharma, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $16 |
How this compares
$13,825,921 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Doral
- Jorge VenereoDoral$4.4M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.